Drug Profile


Alternative Names: 5,6-Dihydro-5-azacyctidine; NSC 26480; NSC 264880

Latest Information Update: 06 Jan 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer ILEX Oncology Inc; MGI Pharma
  • Class Small molecules
  • Mechanism of Action RNA methylation inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Mesothelioma; Prostate cancer

Most Recent Events

  • 06 Jan 1998 Discontinued-I for Cancer in USA (Unknown route)
  • 06 Jan 1998 Discontinued-II for Mesothelioma in USA (IV-infusion)
  • 06 Jan 1998 Discontinued-II for Prostate cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top